Editorial Excellence and Integrity

Why are our solutions trusted globally?

A big reason is the high quality of our drug information and medication safety content and the rigorous development process and editorial philosophy behind it.

  • Our content development process seeks to balance the need to review and validate information with the need to update content as promptly as possible.
  • Our content is evidence-based, reviewed, and developed from literature and resources generally relied upon in the healthcare community.
  • Complex topic discussions are synthesized to promote clear, concise information for use at the point of care.
  • We maintain long-standing relationships with pharmaceutical companies to obtain timely information on product availability, drug pricing, and attributes. However, our content is published under our proprietary editorial policies intended to keep the information unbiased.
  • We do not provide pharma companies with statistics reflecting end user usage habits.

Need more information?

Call us or fill out our online form and we'll have someone contact you!

Contact a Representative

855.633.0577 (US & Canada)
+1 330.650.6506 (International)

Clinical Drug Information Editorial Process

Launching New Monographs

  • FDA or Health Canada approvals, regulatory, manufacturer, and scientific reports launch the development of new drug monographs.
  • Development begins with aggregate sources:
    • Product labeling
    • Base pharmacology studies
    • Clinical trials
  • New referential monographs are developed first and then used to synthesize integrated drug data content.
  • Medication patient education leaflets and drug interaction information are updated concurrently with core drug information and monographs.

Developing Content

  • Data acquisition professionals conduct daily surveillance of industry activity and primary literature so that our information reflects contemporary medical practices and promotes relevance and clarity of content.
  • Content synthesized, managed, and reviewed by a team of nearly 150 advanced-degreed clinicians:
    • Full-time, in-house clinical teams include more than 70 pharmacists, as well as physicians, nurses, and medical technologists
  • Internal and external contributors discuss unique drug properties.

Ongoing Research

  • Further research and regular review of information helps identify relevant medical information (e.g., adverse drug reaction reports, clinical practice guidelines):
    • Medical journals
    • News sources
    • International sites
    • Industry websites (e.g., CDC, pharmaceutical manufacturers)

External Review

  • Monographs are reviewed by members of a diverse board of more than 260 external contributors who are specialists and practicing experts in their own therapeutic area, including physicians, nurses, dental professionals, and dieticians.

Clinical Quality Control

  • Clinical Quality Control review tests that content works correctly within our software and returns appropriate clinical results.
  • Cross-functional team representing content, technology, product management, and implementation employs complex “edge test cases” for which a clinician must verify the results.


  • Delivery of new content to you:
    • Instant online and mobile publication of newly completed reference monographs
    • Daily, weekly, or monthly updates of new drug data content

Continuous Updating

  • Review of clinical literature, regulatory agency reports, and clinical feedback on an ongoing basis to identify new or updated drug information.
  • Research conducted at least once weekly to update information pertaining to medication guides, Risk Evaluation and Mitigation Strategies (REMS), and U.S. drug shortages.
  • Ongoing review of pharmaceutical manufacturer announcements and publications to find information on:
    • New drug availability
    • New dosage forms
    • Revisions to contraindications, warnings, drug interactions
    • Other labeling changes
  • Internal clinical team also monitors available information from the medical science arena:
    • Routine review of published literature within key therapeutic areas
    • Coordinating input related to clinical guidelines and clinical practice based upon contributors’ subject matter expertise

Revisions and Updates

  • New or revised clinical information discovered during ongoing review prompts updates to existing content, following the same rigorous vetting process.